Home Tools
Log in
Cart

Search Result

Search Results for " ctla-4 "

16

Compounds

Cat No. Product Name Synonyms Targets
T3189 B7/CD28 interaction inhibitor 1 CTLA-4 inhibitor Others
B7/CD28 interaction inhibitor 1 (CTLA-4 inhibitor) is a potent CTLA-4 inhibitor.
T78261 Anti-Mouse CTLA-4 Antibody (9D9)
Anti-Mouse CTLA-4 Antibody is a mouse-derived IgG2b inhibitor targeting CTLA-4 in murine systems.
T9906 Ipilimumab Others
Ipilimumab (anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor.
T77466 Tremelimumab Ticilimumab,CP-675206 Others
Tremelimumab is a cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blocking antibody.Tremelimumab is often used in combination with Durvalumab for the treatment of solid cancers such as hepatocellular carcinoma and l...
T6741 SPDP SPDP Crosslinker Others
SPDP is a short-chain crosslinker, which is used for amine-to-sulfhydryl conjugation via NHS-ester and pyridyldithiol reactive groups that form cleavable (reducible) disulfide bonds with cysteine sulfhydryls. SPDP could ...
T81329 Quavonlimab MK-1308
Quavonlimab (MK-1308) is a novel antibody targeting CTLA-4 [1].
T76952 Zalifrelimab
Zalifrelimab (AGEN1884) is a fully human IgG1 monoclonal antibody that targets CTLA-4 (CTLA-4), functioning by antagonizing the CTLA-4-signaling-regulated inhibitory checkpoints of immune cell activation.
T77103 Nurulimab
Nurulimab (BCD-145) is a humanized monoclonal antibody targeting cytotoxic T lymphocyte antigen-4 (anti-CTLA-4). It has potential applications in melanoma research [1].
T82268 Gotistobart BNT 316,ONC-392
Gotistobart (ONC-392) is a humanized anti-CTLA-4 antibody that enhances immunotherapy by selectively depleting regulatory T cells (Treg) within the tumor microenvironment [1].
T81124 Sovipostobart
Sovipostobart, an immunoglobulin G1-kappa monoclonal antibody targeting CTLA-4 in Homo sapiens, features a cleavable prodomain. This compound serves as both an immunostimulant and antineoplastic [1].
T76728 Vudalimab
Vudalimab, a fully humanized bispecific monoclonal antibody, effectively inhibits both PD-1 and CTLA-4 immune checkpoint receptors. This dual action facilitates the selective activation of T-cells targeting tumors.
T77072 Lorigerlimab
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting (DART) antibody that blocks both PD-1 and CTLA-4, enhancing T-cell responses. It is under investigation for the treatment of metastatic castration-res...
T80598 Davoceticept CD80 vIgD-Fc,ALPN-202
Davoceticept (ALPN-202; CD80 vIgD-Fc), a monoclonal antibody that targets CTLA-4, is comprised of the (1-107) fragment of CD80 fused to the IGHG1 Fc domain through a peptidyl linker. It is commonly produced in CHO (Chine...
T76859 Bavunalimab
Bavunalimab (Anti-Human CTLA4xLAG3), a bispecific human monoclonal antibody targeting CTLA-4 and LAG-3, activates T cells in NSG mice and is utilized in cancer research [1].
T76933 Botensilimab
Botensilimab (AGEN 1181), a humanized monoclonal antibody targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4), functions as an activator of both innate and adaptive immunity. It is currently being researched for its pote...
T76968 Tuvonralimab
Tuvonralimab (PSB-205; QL1706), comprising a combination of Iparomlimab and Tuvonralimab [1], functions as a dual immune checkpoint inhibitor through its formulation of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies.
TargetMol